Beer Netta, Shinar Eilat, Novack Lena, Safi Jamal, Soliman Hassan, Yaari Arieh, Goldman-Levi Ronit, Yahalom Vered, Bolotin Arkadi, Sarov Batia
Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Transfusion. 2006 Oct;46(10):1822-8. doi: 10.1111/j.1537-2995.2006.00972.x.
Screening blood units for hepatitis C virus (HCV) with nucleic acid testing (NAT) reduces the risk associated with the long "window period" (8-9 weeks) after HCV infection. The feasibility of adding the HCV core antigen assay in pools to the existing anti-HCV individual screening was examined as an alternative of NAT, for early detection of HCV.
Eighteen HCV seroconversion panels were tested for HCV antibodies, HCV antigen, and HCV RNA. Each sample was tested for HCV antigen individually and in pools of 3, 6, and 12. Statistical analyses included estimation of time until detection of the first positive HCV antigen bleed in each pool size, with a locally weighted regression (LOWESS) model. Sensitivity was calculated compared to NAT.
Detection of HCV antigen in individual samples and in pools of 3 and 6 significantly preceded the detection of antibodies by 63, 53, and 46 days, respectively. Although the sensitivity of the HCV antigen test decreased with the increase in pool size, the estimated overall sensitivity of the "two-stage" antigen and antibody screening (where NAT of individual samples was the gold standard) was not significantly different between individual and the different pool sizes.
Screening for HCV antigen in pools of 6 can be considered an efficient and easier-to-implement alternative to the costly NAT for identifying blood donors in the seroconversion period. It may offer a cost-effective approach in resource utilization in poor countries, that, after the implementation of HCV antibody testing, want to further improve blood safety.
采用核酸检测(NAT)对血液单位进行丙型肝炎病毒(HCV)筛查可降低HCV感染后长“窗口期”(8 - 9周)相关的风险。研究了将HCV核心抗原混合检测法添加到现有的抗HCV个体筛查中作为NAT的替代方法用于HCV早期检测的可行性。
对18个HCV血清转化样本组进行了HCV抗体、HCV抗原和HCV RNA检测。每个样本分别进行HCV抗原检测,以及3个、6个和12个样本的混合检测。统计分析包括使用局部加权回归(LOWESS)模型估计每个混合样本量中首次检测到HCV抗原阳性出血的时间。与NAT相比计算灵敏度。
个体样本以及3个和6个样本混合检测中HCV抗原的检测分别比抗体检测提前63天、53天和46天。虽然HCV抗原检测的灵敏度随混合样本量增加而降低,但“两阶段”抗原和抗体筛查(以个体样本的NAT为金标准)的估计总体灵敏度在个体和不同混合样本量之间无显著差异。
对于在血清转化期识别献血者,6个样本混合检测HCV抗原可被视为一种有效且更易于实施的替代昂贵NAT的方法。对于在实施HCV抗体检测后希望进一步提高血液安全性的贫穷国家,它可能提供一种资源利用方面具有成本效益的方法。